Pharma & Healthcare
Tumor Necrosis Factor Inhibitors
- Types
- Enbrel · Remicade · Humira
- Applications
- Ischemic Stroke · Parkinson's Diseases · Multiple Sclerosis
5 editions22 December 2025
Compare the product scope, applications and research editions relevant to your next decision.
Pharma & Healthcare
5 editions22 December 2025
Pharma & Healthcare
Darbepoetin alfa (INN) is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with…
5 editions23 December 2025
Pharma & Healthcare
5 editions29 December 2025
Pharma & Healthcare
5 editions21 December 2025
Pharma & Healthcare
5 editions29 December 2025
Pharma & Healthcare
5 editions22 December 2025
Pharma & Healthcare
5 editions30 December 2025
Pharma & Healthcare
5 editions21 December 2025
Pharma & Healthcare
5 editions27 December 2025
Pharma & Healthcare
5 editions2 January 2026
Pharma & Healthcare
5 editions22 December 2025
Pharma & Healthcare
5 editions22 December 2025